Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $33.06

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have earned an average recommendation of “Hold” from the eighteen analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $33.0625.

A number of equities analysts have weighed in on APLS shares. TD Cowen dropped their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Wells Fargo & Company initiated coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 15th. They issued an “overweight” rating and a $32.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 1st. HC Wainwright lowered their target price on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Finally, Wolfe Research assumed coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They set a “peer perform” rating for the company.

Insiders Place Their Bets

In related news, CFO Timothy Eugene Sullivan sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00. Following the completion of the sale, the chief financial officer directly owned 110,936 shares of the company’s stock, valued at $3,109,536.08. The trade was a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $20.06, for a total transaction of $100,300.00. Following the completion of the transaction, the general counsel owned 108,730 shares in the company, valued at $2,181,123.80. This represents a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 87,373 shares of company stock valued at $2,084,036. 6.80% of the stock is currently owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC lifted its stake in shares of Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Apellis Pharmaceuticals by 206.8% during the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after purchasing an additional 1,373 shares during the period. Osaic Holdings Inc. increased its holdings in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares during the last quarter. Allworth Financial LP lifted its stake in Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after buying an additional 857 shares during the period. Finally, Quantbot Technologies LP bought a new position in Apellis Pharmaceuticals during the third quarter worth about $64,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Trading Up 0.7%

APLS stock opened at $23.79 on Friday. The business has a fifty day moving average price of $22.94 and a 200 day moving average price of $22.21. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10. Apellis Pharmaceuticals has a fifty-two week low of $16.10 and a fifty-two week high of $35.72. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of 76.74 and a beta of 0.37.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.03 by $0.64. The company had revenue of $458.58 million for the quarter, compared to analysts’ expectations of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business’s revenue for the quarter was up 133.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.46) earnings per share. Analysts expect that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).